{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:07:17Z","timestamp":1793995637249,"version":"4.8.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02761-x","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:01:38Z","timestamp":1782774098000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tetrahedral DNA nano-PROTACs enable enhanced ocular penetration and efficient nucleolin degradation for choroidal neovascularization therapy"],"prefix":"10.1038","volume":"11","author":[{"given":"Jiayi","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinghui","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiyun","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyu","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubens","family":"Belfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Antonio Brant","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3195-6948","authenticated-orcid":false,"given":"Songbo","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"2761_CR1","doi-asserted-by":"publisher","first-page":"e1175","DOI":"10.1016\/S2214-109X(25)00143-3","volume":"13","author":"GBDGA Collaborators","year":"2025","unstructured":"Collaborators, G. B. D. G. A. Global burden of vision impairment due to age-related macular degeneration, 1990-2021, with forecasts to 2050: a systematic analysis for the global burden of disease study 2021. Lancet Glob. Health 13, e1175\u2013e1190 (2025).","journal-title":"Lancet Glob. Health"},{"key":"2761_CR2","first-page":"513","volume":"117","author":"A Stahl","year":"2020","unstructured":"Stahl, A. The diagnosis and treatment of age-related macular degeneration. Dtsch. Arztebl. Int 117, 513\u2013520 (2020).","journal-title":"Dtsch. Arztebl. Int"},{"key":"2761_CR3","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1159\/000518822","volume":"68","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Global incidence, progression, and risk factors of age-related macular degeneration and projection of disease statistics in 30 years: A modeling study. Gerontology 68, 721\u2013735 (2022).","journal-title":"Gerontology"},{"key":"2761_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ophtha.2024.12.018","volume":"132","author":"GA Vemulakonda","year":"2025","unstructured":"Vemulakonda, G. A. et al. Age-related macular degeneration preferred practice pattern. Ophthalmology 132, 1\u201374 (2025).","journal-title":"Ophthalmology"},{"key":"2761_CR5","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3390\/biom12111629","volume":"12","author":"RH ElSheikh","year":"2022","unstructured":"ElSheikh, R. H., Chauhan, M. Z. & Sallam, A. B. Current and novel therapeutic approaches for treatment of neovascular age-related macular degeneration. Biomolecules 12, 1629 (2022).","journal-title":"Biomolecules"},{"key":"2761_CR6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ajo.2015.06.023","volume":"160","author":"JL Prenner","year":"2015","unstructured":"Prenner, J. L. et al. Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am. J. Ophthalmol. 160, 725\u2013731 (2015).","journal-title":"Am. J. Ophthalmol."},{"key":"2761_CR7","doi-asserted-by":"publisher","first-page":"100906","DOI":"10.1016\/j.preteyeres.2020.100906","volume":"82","author":"PS Mettu","year":"2021","unstructured":"Mettu, P. S., Allingham, M. J. & Cousins, S. W. Incomplete response to anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. Prog. Retin. Eye Res. 82, 100906 (2021).","journal-title":"Prog. Retin. Eye Res."},{"key":"2761_CR8","doi-asserted-by":"publisher","first-page":"149479","DOI":"10.1016\/j.gene.2025.149479","volume":"957","author":"K Prakash","year":"2025","unstructured":"Prakash, K. et al. Investigating the multifaceted role of nucleolin in cellular function and cancer: Structure, regulation, and therapeutic implications. Gene 957, 149479 (2025).","journal-title":"Gene"},{"key":"2761_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2174\/0115680096370250250513115130","volume":"26","author":"K Ramasamy","year":"2026","unstructured":"Ramasamy, K., Arun, R., Khan, S. F., Prince, S. & Nagarajan, A. K. Nucleolin as a crucial player in head and neck cancer: diagnostic and therapeutic perspectives. Curr. Cancer Drug Targets 26, 129\u2013135 (2026).","journal-title":"Curr. Cancer Drug Targets"},{"key":"2761_CR10","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1182\/blood-2005-07-2961","volume":"107","author":"Y Huang","year":"2006","unstructured":"Huang, Y. et al. The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. Blood 107, 3564\u20133571 (2006).","journal-title":"Blood"},{"key":"2761_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s10637-013-0045-6","volume":"32","author":"JE Rosenberg","year":"2014","unstructured":"Rosenberg, J. E. et al. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest. New Drugs 32, 178\u2013187 (2014).","journal-title":"Invest. New Drugs"},{"key":"2761_CR12","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.ijbiomac.2019.11.118","volume":"155","author":"R Yazdian-Robati","year":"2020","unstructured":"Yazdian-Robati, R. et al. Therapeutic applications of AS1411 aptamer, an update review. Int. J. Biol. Macromol. 155, 1420\u20131431 (2020).","journal-title":"Int. J. Biol. Macromol."},{"key":"2761_CR13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/d41586-019-00879-3","volume":"567","author":"M Scudellari","year":"2019","unstructured":"Scudellari, M. Protein-slaying drugs could be the next blockbuster therapies. Nature 567, 298\u2013300 (2019).","journal-title":"Nature"},{"key":"2761_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M Bekes","year":"2022","unstructured":"Bekes, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181\u2013200 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2761_CR15","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/j.scib.2024.05.017","volume":"69","author":"L Kong","year":"2024","unstructured":"Kong, L. et al. An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer. Sci. Bull. 69, 2122\u20132135 (2024).","journal-title":"Sci. Bull."},{"key":"2761_CR16","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","volume":"9","author":"G Zhong","year":"2024","unstructured":"Zhong, G., Chang, X., Xie, W. & Zhou, X. Targeted protein degradation: advances in drug discovery and clinical practice. Signal Transduct. Target. Ther. 9, 308 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2761_CR17","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","volume":"21","author":"B Dale","year":"2021","unstructured":"Dale, B. et al. Advancing targeted protein degradation for cancer therapy. Nat. Rev. Cancer 21, 638\u2013654 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"2761_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.semcancer.2020.02.006","volume":"67","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. PROTACs: A novel strategy for cancer therapy. Semin. Cancer Biol. 67, 171\u2013179 (2020).","journal-title":"Semin. Cancer Biol."},{"key":"2761_CR19","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.tips.2023.05.008","volume":"44","author":"Z Yang","year":"2023","unstructured":"Yang, Z., Pang, Q., Zhou, J., Xuan, C. & Xie, S. Leveraging aptamers for targeted protein degradation. Trends Pharmacol. Sci. 44, 776\u2013785 (2023).","journal-title":"Trends Pharmacol. Sci."},{"key":"2761_CR20","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aab1433","volume":"348","author":"GE Winter","year":"2015","unstructured":"Winter, G. E. et al. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376\u20131381 (2015).","journal-title":"Science"},{"key":"2761_CR21","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1021\/acs.jmedchem.2c01557","volume":"66","author":"M Chen","year":"2023","unstructured":"Chen, M. et al. Inducible degradation of oncogenic nucleolin using an aptamer-based PROTAC. J. Med. Chem. 66, 1339\u20131348 (2023).","journal-title":"J. Med. Chem."},{"key":"2761_CR22","doi-asserted-by":"publisher","first-page":"15818","DOI":"10.1002\/anie.201916390","volume":"59","author":"A Keller","year":"2020","unstructured":"Keller, A. & Linko, V. Challenges and perspectives of DNA nanostructures in biomedicine. Angew. Chem.-Int Edit. 59, 15818\u201315833 (2020).","journal-title":"Angew. Chem.-Int Edit."},{"key":"2761_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202400810","volume":"26","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y., Li, Y., Fang, B., Du, Y. & Peng, P. Framework nucleic acids: Innovative tools for cellular sensing and therapeutics. Chembiochem 26, e202400810 (2025).","journal-title":"Chembiochem"},{"key":"2761_CR24","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1080\/17425247.2023.2276285","volume":"20","author":"J Li","year":"2023","unstructured":"Li, J., Yan, R., Shi, S. & Lin, Y. Recent progress and application of the tetrahedral framework nucleic acid materials on drug delivery. Expert Opin. Drug Deliv. 20, 1511\u20131530 (2023).","journal-title":"Expert Opin. Drug Deliv."},{"key":"2761_CR25","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1021\/acsami.2c18042","volume":"15","author":"R Wang","year":"2023","unstructured":"Wang, R. et al. Framework nucleic acids as blood-retinal-barrier-penetrable nanocarrier for periocular administration. ACS Appl. Mater. Interfaces 15, 541\u2013551 (2023).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2761_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2353\/ajpath.2007.061237","volume":"171","author":"K Nishijima","year":"2007","unstructured":"Nishijima, K. et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. Pathol. 171, 53\u201367 (2007).","journal-title":"Am. J. Pathol."},{"key":"2761_CR27","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.ophtha.2009.03.017","volume":"116","author":"DN Papadopoulou","year":"2009","unstructured":"Papadopoulou, D. N., Mendrinos, E., Mangioris, G., Donati, G. & Pournaras, C. J. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration. Ophthalmology 116, 1755\u20131761 (2009).","journal-title":"Ophthalmology"},{"key":"2761_CR28","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1167\/iovs.10-5842","volume":"52","author":"S Sacu","year":"2011","unstructured":"Sacu, S. et al. Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion. Invest. Ophthalmol. Vis. Sci. 52, 3046\u20133050 (2011).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2761_CR29","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1172\/JCI65157","volume":"122","author":"T Kurihara","year":"2012","unstructured":"Kurihara, T., Westenskow, P. D., Bravo, S., Aguilar, E. & Friedlander, M. Targeted deletion of Vegfa in adult mice induces vision loss. J. Clin. Invest. 122, 4213\u20134217 (2012).","journal-title":"J. Clin. Invest."},{"key":"2761_CR30","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1167\/iovs.06-1171","volume":"48","author":"P Heiduschka","year":"2007","unstructured":"Heiduschka, P. et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest. Ophthalmol. Vis. Sci. 48, 2814\u20132823 (2007).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2761_CR31","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ophtha.2008.09.046","volume":"116","author":"T Ueta","year":"2009","unstructured":"Ueta, T., Yanagi, Y., Tamaki, Y. & Yamaguchi, T. Cerebrovascular accidents in ranibizumab. Ophthalmology 116, 362 (2009).","journal-title":"Ophthalmology"},{"key":"2761_CR32","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/j.ophtha.2011.06.001","volume":"118","author":"T Ueta","year":"2011","unstructured":"Ueta, T. et al. Stroke and anti-VEGF therapy. Ophthalmology 118, 2093\u20132093 e2092 (2011).","journal-title":"Ophthalmology"},{"key":"2761_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba7457","volume":"6","author":"Z Wang","year":"2020","unstructured":"Wang, Z. et al. Wnt signaling activates MFSD2A to suppress vascular endothelial transcytosis and maintain blood-retinal barrier. Sci. Adv. 6, eaba7457 (2020).","journal-title":"Sci. Adv."},{"key":"2761_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09029-9","volume":"10","author":"C Wiraja","year":"2019","unstructured":"Wiraja, C. et al. Framework nucleic acids as programmable carrier for transdermal drug delivery. Nat. Commun. 10, 1147 (2019).","journal-title":"Nat. Commun."},{"key":"2761_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06606-2","volume":"9","author":"SH Shin","year":"2018","unstructured":"Shin, S. H. et al. Aberrant expression of CITED2 promotes prostate cancer metastasis by activating the nucleolin-AKT pathway. Nat. Commun. 9, 4113 (2018).","journal-title":"Nat. Commun."},{"key":"2761_CR36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10456-009-9137-5","volume":"12","author":"V Fogal","year":"2009","unstructured":"Fogal, V., Sugahara, K. N., Ruoslahti, E. & Christian, S. Cell surface nucleolin antagonist causes endothelial cell apoptosis and normalization of tumor vasculature. Angiogenesis 12, 91\u2013100 (2009).","journal-title":"Angiogenesis"},{"key":"2761_CR37","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1002\/jcp.26205","volume":"233","author":"AC Dhez","year":"2018","unstructured":"Dhez, A. C. et al. Targeted therapy of human glioblastoma via delivery of a toxin through a peptide directed to cell surface nucleolin. J. Cell. Physiol. 233, 4091\u20134105 (2018).","journal-title":"J. Cell. Physiol."},{"key":"2761_CR38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12951-025-03919-5","volume":"24","author":"Y Hao","year":"2025","unstructured":"Hao, Y. et al. Aptamer-engineered NIR-II ru-doped carbon quantum dot nanozyme for photoacoustic imaging-guided synergistic photothermal and catalytic cancer therapy. J. Nanobiotechnol. 24, 68 (2025).","journal-title":"J. Nanobiotechnol."},{"key":"2761_CR39","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1021\/acscentsci.8b00383","volume":"4","author":"H Ding","year":"2018","unstructured":"Ding, H. et al. DNA nanostructure-programmed like-charge attraction at the cell-membrane interface. ACS Central Sci 4, 1344\u20131351 (2018).","journal-title":"ACS Central Sci"},{"key":"2761_CR40","doi-asserted-by":"publisher","first-page":"8783","DOI":"10.1021\/nn202774x","volume":"5","author":"J Li","year":"2011","unstructured":"Li, J. et al. Self-assembled multivalent DNA nanostructures for noninvasive intracellular delivery of immunostimulatory CpG oligonucleotides. ACS Nano 5, 8783\u20138789 (2011).","journal-title":"ACS Nano"},{"key":"2761_CR41","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1021\/nl1040836","volume":"11","author":"Q Mei","year":"2011","unstructured":"Mei, Q. et al. Stability of DNA origami nanoarrays in cell lysate. Nano Lett 11, 1477\u20131482 (2011).","journal-title":"Nano Lett"},{"key":"2761_CR42","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12951-024-02365-z","volume":"22","author":"W Zou","year":"2024","unstructured":"Zou, W., Lu, J., Zhang, L. & Sun, D. Tetrahedral framework nucleic acids for improving wound healing. J. Nanobiotechnol. 22, 113 (2024).","journal-title":"J. Nanobiotechnol."},{"key":"2761_CR43","doi-asserted-by":"publisher","first-page":"11397","DOI":"10.1021\/acsami.0c00874","volume":"12","author":"S Lin","year":"2020","unstructured":"Lin, S. et al. Antioxidative and angiogenesis-promoting effects of tetrahedral framework nucleic acids in diabetic wound healing with activation of the Akt\/Nrf2\/HO-1 pathway. ACS Appl. Mater. Interfaces 12, 11397\u201311408 (2020).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2761_CR44","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1172\/JCI107470","volume":"52","author":"EA Jaffe","year":"1973","unstructured":"Jaffe, E. A., Nachman, R. L., Becker, C. G. & Minick, C. R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Invest. 52, 2745\u20132756 (1973).","journal-title":"J. Clin. Invest."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02761-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02761-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02761-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:01:39Z","timestamp":1782774099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02761-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2761"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02761-x","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"253"}}